Charles River Laboratories International, Inc. (CRL) Stake Decreased by Seven Eight Capital LP

Seven Eight Capital LP lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 48.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,500 shares of the medical research company’s stock after selling 5,100 shares during the period. Seven Eight Capital LP’s holdings in Charles River Laboratories International were worth $556,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Alps Advisors Inc. lifted its stake in Charles River Laboratories International by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock valued at $541,000 after acquiring an additional 14 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Charles River Laboratories International by 0.5% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,953 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 33 shares in the last quarter. Bbva Compass Bancshares Inc. lifted its stake in Charles River Laboratories International by 0.8% in the 2nd quarter. Bbva Compass Bancshares Inc. now owns 6,004 shares of the medical research company’s stock valued at $607,000 after acquiring an additional 50 shares in the last quarter. World Asset Management Inc lifted its stake in Charles River Laboratories International by 2.2% in the 2nd quarter. World Asset Management Inc now owns 2,762 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 59 shares in the last quarter. Finally, Utah Retirement Systems lifted its stake in Charles River Laboratories International by 1.2% in the 1st quarter. Utah Retirement Systems now owns 8,597 shares of the medical research company’s stock valued at $773,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 95.82% of the company’s stock.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) opened at 106.02 on Friday. The stock’s 50 day moving average price is $103.01 and its 200-day moving average price is $95.28. Charles River Laboratories International, Inc. has a 52 week low of $67.20 and a 52 week high of $109.59. The company has a market cap of $5.05 billion, a PE ratio of 27.94 and a beta of 0.99.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The company had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. During the same quarter last year, the company earned $1.20 earnings per share. The company’s revenue for the quarter was up 8.1% on a year-over-year basis. Analysts expect that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Charles River Laboratories International, Inc. (CRL) Stake Decreased by Seven Eight Capital LP” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://stocknewstimes.com/2017/09/17/charles-river-laboratories-international-inc-crl-stake-decreased-by-seven-eight-capital-lp.html.

Several equities research analysts have commented on CRL shares. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 target price on the stock in a research note on Wednesday, July 12th. Jefferies Group LLC restated a “buy” rating and issued a $121.00 target price on shares of Charles River Laboratories International in a research note on Friday, June 30th. BidaskClub cut Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Robert W. Baird restated a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research note on Friday, September 1st. Finally, Barclays PLC restated a “hold” rating and issued a $102.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $98.55.

In other news, insider Davide Molho sold 5,982 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $107.55, for a total value of $643,364.10. Following the transaction, the insider now owns 22,714 shares in the company, valued at $2,442,890.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman James C. Foster sold 43,154 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $100.00, for a total value of $4,315,400.00. Following the completion of the transaction, the chairman now owns 361,178 shares in the company, valued at approximately $36,117,800. The disclosure for this sale can be found here. Insiders sold 79,982 shares of company stock worth $7,951,868 in the last 90 days. Corporate insiders own 2.20% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply